IP Library Granted Patent US 9,989,535
Granted Patent B2
US 9,989,535 · App. 15/282,430 · Granted Jun 5, 2018

Methods and reagents for analyzing protein-protein interfaces

Inventors: Gregory L. Verdine (Bedford, MA); M. James Nichols (Charlestown, MA); Sharon A. Townson (Cambridge, MA); Uddhav Kumar Shigdel (Cambridge, MA); Seung-Joo Lee (Cambridge, MA); Dylan T. Stiles (Cambridge, MA); Neville J. Anthony (Northborough, MA)
Assignee: Warp Drive Bio, Inc.
G01N33/6845C07K1/086C07K1/13C07K5/0215C07K5/06034C07K5/0808C07K7/64C07K7/645C12Q1/533G01N33/566G01N2333/82G01N2333/90209G01N2410/08G01N2500/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,989,535
App. No.
15/282,430
Granted
Jun 5, 2018
Kind
B2
Abstract

The present disclosure provides methods and reagents useful for analyzing protein-protein interfaces such as interfaces between a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein. In some embodiments, the target and/or presenter proteins are intracellular proteins. In some embodiments, the target and/or presenter proteins are mammalian proteins.

Claims (15)

1. A compound having the structure:

A-L-B,

wherein A comprises a cyclophilin binding moiety having the structure of Formula IV:

Z 5 , and Z 6 are each, independently, hydroxyl, optionally substituted C 1 -C 6 alkyl, optionally substituted C 1 -C 6 heteroalkyl, or Z 5 and Z 6 combine to form, with the atoms to which they are attached, an optionally substituted 10 to 40 member macrocycles;

at least one of Z 5 or Z 6 comprises a point of attachment to L;

e is 0, 1, 2, 3, or 4;

each R 7 is, independently, hydroxyl, cyano, optionally substituted amino, halogen, thiol, optionally substituted C 1 -C 6 alkyl, optionally substituted C 2 -C 6 alkenyl, optionally substituted C 2 -C 6 alkynyl, optionally substituted C 1 -C 6 heteroalkyl, optionally substituted C 2 -C 6 heteroalkenyl, optionally substituted C 2 -C 6 heteroalkynyl, optionally substituted C 3 -C 10 carbocyclyl, optionally substituted C 6 -C 10 aryl, optionally substituted C 6 -C 10 aryl C 1 -C 6 alkyl, optionally substituted C 2 -C 6 heterocyclyl, or optionally substituted C 2 -C 6 heterocyclyl C 1 -C 6 alkyl; and

R 8 is hydrogen, optionally substituted C 1 -C 6 alkyl, optionally substituted C 2 -C 6 alkenyl, optionally substituted C 2 -C 6 alkynyl, optionally substituted aryl, C 3 -C 7 carbocyclyl, optionally substituted C 6 -C 10 aryl C 1 -C 6 alkyl, or optionally substituted C 3 -C 7 carbocyclyl C 1 -C 6 alkyl;

L is a linker having the structure:

A 1 -(B 1 ) f -(C 1 ) g -(B 2 ) h -(D)-(B 3 ) i -(C 2 ) i -(B 4 ) k -A 2

wherein A 1 is a bond between the linker and cyclophilin binding moiety; A 2 is a bond between the cross-linking group and the linker; B 1 , B 2 , B 3 , and B 4 each, independently, is selected from optionally substituted C 1 -C 2 alkyl, optionally substituted C 1 -C 3 heteroalkyl, O, S, and NR N ; R N is hydrogen, optionally substituted C 1-4 alkyl, optionally substituted C 2-4 alkenyl, optionally substituted C 2-4 alkynyl, optionally substituted C 2-6 heterocyclyl, optionally substituted C 6-12 aryl, or optionally substituted C 1-7 heteroalkyl; C 1 and C 2 are each, independently, selected from carbonyl, thiocarbonyl, sulphonyl, or phosphoryl; f, g, h, I, j, and k are each, independently, 0 or 1; and D is optionally substituted C 1-10 alkyl, optionally substituted C 2-10 alkenyl, optionally substituted C 2-10 alkynyl, optionally substituted C 2-6 heterocyclyl, optionally substituted C 6-12 aryl, optionally substituted C 2 -C 10 polyethylene glycol, or optionally substituted C 1-10 heteroalkyl, or a chemical bond linking A 1 -(B 1 ) f -(C 1 ) g -(B 2 ) h - to -(B 3 ) i -(C 2 ) j -(B 4 ) k -A 2 ; and

B comprises a cross-linking group, wherein the cross-linking group is a mixed disulfide, maleimide, vinyl sulfone, vinyl ketone, alkyl halide, isocyanate, isothiocyanate, sulfonyl chloride, acid halide, active ester, acid anhydride, acylazide, imidoester, haloheteroaryl, diazo compound, carbodiimide, hydrazide, alkoxyamine, azide, or alkyne.

2. The compound of claim 1 , wherein the cross-linking group is a mixed disulfide, a maleimide, a vinyl sulfone, a vinyl ketone, or an alkyl chloride.

3. The compound of claim 1 , wherein the interaction between the cyclophilin binding moiety and cyclophilin is non-covalent.

4. The compound of claim 1 , wherein the cyclophilin binding moiety is a cyclophilin binding moiety capable of binding PP1A, CYPB, CYPC, CYP40, CYPE, CYPD, NKTR, SRCyp, CYPH, CWC27, CYPL1, CYP60, CYPJ, PPIL4, PPIL6, RANBP2, or PPWD1.

Assignments (3)
SECURITY INTEREST Recorded Jun 25, 2025
From: REVOLUTION MEDICINES, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT
Reel/Frame 071721/0025 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 24, 2019
From: WARP DRIVE BIO, INC.
To: REVOLUTION MEDICINES, INC.
Reel/Frame 050473/0976 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 24, 2018
From: VERDINE, GREGORY L.; NICHOLS, MATTHEW JAMES; TOWNSON, SHARON A.; SHIGDEL, UDDHAV KUMAR; LEE, SEUNG-JOO; STILES, DYLAN T.; ANTHONY, NEVILLE J.
To: WARP DRIVE BIO, INC.
Reel/Frame 045625/0038 →
Continuity (2)
Provisional Application 62235896 · Oct 1, 2015
Related Publication 20170097359A1 · Apr 6, 2017